This is a preview of subscription content, log in via an institution to check access.
References
Mellsop H. New antifungal agents needed for immuno-compromised patients. Inpharma 1995 Dec 2; 1015: 9–10
Jack D. Voriconazole: a natural successor to fluconazole? Inpharma 1998 Jul 18; 1146: 7–8
New antifungals highlighted at ICAAC. Marketletter 1997 Nov 17; 24: 26–7
Martin MV, Yeats J, Hitchcock CA. Voriconazole (UK-109,496): a novel, wide-spectrum triazole derivative for the treatment of fungal infections: antifungal activity in experimental Aspergillus endocarditis. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15–18; New Orleans, 114
Clancy CJ, Nguyen MH. In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur J Clin Microbiol Infect Dis 1998 Aug; 17: 573–5
Cuenca-Estrella M, Rodríguez-Tudela JL, Mellado E, et al. Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus. J Antimicrob Chemother 1998 Oct; 42: 531–3
Wildfeuer A, Seidl HP, Paule I, et al. In vitro activity of voriconazole against yeasts, moulds and dermatophytes in comparison with fluconazole, amphotericin B and griseofulvin. Arzneimittel Forschung 1997 Nov; 47: 1257–63
Kauffman CA, Zarins LT. In vitro activity of voriconazole against Candida species. Diagn Microbiol Infect Dis 1998 May; 31: 297–300
Rights and permissions
About this article
Cite this article
Voriconazole. Drugs R&D 1, 187–188 (1999). https://doi.org/10.2165/00126839-199901020-00020
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-199901020-00020